Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07207070) titled 'A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.
Condition:
Breast Cancer
Intervention:
Drug: JS105
Drug: Dalpiciclib
Recruitment Status: Not recr...